201 related articles for article (PubMed ID: 22668803)
21. Two case reports: Whole genome sequencing of two clinical macrolide-resistant Mycoplasma pneumoniae isolates with different responses to azithromycin.
Li S; Sun H; Liu F; Feng Y; Zhao H; Xue G; Yan C
Medicine (Baltimore); 2016 Sep; 95(38):e4963. PubMed ID: 27661056
[TBL] [Abstract][Full Text] [Related]
22. Therapeutic efficacy of macrolides, minocycline, and tosufloxacin against macrolide-resistant Mycoplasma pneumoniae pneumonia in pediatric patients.
Kawai Y; Miyashita N; Kubo M; Akaike H; Kato A; Nishizawa Y; Saito A; Kondo E; Teranishi H; Ogita S; Tanaka T; Kawasaki K; Nakano T; Terada K; Ouchi K
Antimicrob Agents Chemother; 2013 May; 57(5):2252-8. PubMed ID: 23459497
[TBL] [Abstract][Full Text] [Related]
23. Microbiologic and immunologic evaluation of a single high dose of azithromycin for treatment of experimental Mycoplasma pneumoniae pneumonia.
Ríos AM; Fonseca-Aten M; Mejías A; Chávez-Bueno S; Katz K; Gómez AM; McCracken GH; Ramilo O; Hardy RD
Antimicrob Agents Chemother; 2005 Sep; 49(9):3970-3. PubMed ID: 16127085
[TBL] [Abstract][Full Text] [Related]
24. [Analysis on antibacterial activity of common antibiotics to Mycoplasma pneumoniae].
Xin DL; Chen XG; Han X
Zhonghua Er Ke Za Zhi; 2009 Apr; 47(4):305-6. PubMed ID: 19555573
[No Abstract] [Full Text] [Related]
25. Detection of macrolide resistant Mycoplasma pneumoniae in England, September 2014 to September 2015.
Brown RJ; Macfarlane-Smith L; Phillips S; Chalker VJ
Euro Surveill; 2015; 20(48):30078. PubMed ID: 26675545
[TBL] [Abstract][Full Text] [Related]
26. Rapidly progressive lung disease in a patient with cystic fibrosis on long-term azithromycin: possible role of mycoplasma infection.
Janahi IA; Abdulwahab A; Elshafie Sittana S; Bush A
J Cyst Fibros; 2005 Mar; 4(1):71-3. PubMed ID: 15752685
[TBL] [Abstract][Full Text] [Related]
27. Clinical Characteristics and Antibiotic Resistance of Mycoplasma Pneumoniae Pneumonia in Hospitalized Chinese Children.
Yuan C; Min FM; Ling YJ; Li G; Ye HZ; Pan JH; Wang L; Xie YP
Comb Chem High Throughput Screen; 2018; 21(10):749-754. PubMed ID: 30636596
[TBL] [Abstract][Full Text] [Related]
28. High prevalence of macrolide resistance in Mycoplasma pneumoniae isolates from adult and adolescent patients with respiratory tract infection in China.
Cao B; Zhao CJ; Yin YD; Zhao F; Song SF; Bai L; Zhang JZ; Liu YM; Zhang YY; Wang H; Wang C
Clin Infect Dis; 2010 Jul; 51(2):189-94. PubMed ID: 20540621
[TBL] [Abstract][Full Text] [Related]
29. Phase-shifting of the transmissibility of macrolide-sensitive and resistant Mycoplasma pneumoniae epidemics in Hong Kong, from 2015 to 2018.
Zhao S; Musa SS; Qin J; He D
Int J Infect Dis; 2019 Apr; 81():251-253. PubMed ID: 30822543
[TBL] [Abstract][Full Text] [Related]
30. [Clinical features and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children].
Chen Y; Tian WM; Chen Q; Zhao HY; Huang P; Lin ZQ; Chen L
Zhongguo Dang Dai Er Ke Za Zhi; 2018 Aug; 20(8):629-634. PubMed ID: 30111471
[TBL] [Abstract][Full Text] [Related]
31. Fuchs syndrome associated with Mycoplasma pneumoniae (Stevens-Johnson syndrome without skin lesions).
Meyer Sauteur PM; Gansser-Kälin U; Lautenschlager S; Goetschel P
Pediatr Dermatol; 2011; 28(4):474-6. PubMed ID: 20678095
[TBL] [Abstract][Full Text] [Related]
32. Multilocus variable-number tandem-repeat analysis-confirmed emergence of a macrolide resistance-associated mutation in Mycoplasma pneumoniae during macrolide therapy for interstitial pneumonia in an immunocompromised child.
Hantz S; Garnier F; Peuchant O; Menetrey C; Charron A; Ploy MC; Bébéar C; Pereyre S
J Clin Microbiol; 2012 Oct; 50(10):3402-5. PubMed ID: 22814468
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the ameliorative effects of Qingfei Tongluo formula and azithromycin on Mycoplasma pneumoniae pneumonia.
Xiao Z; Jiang Y; Gao X; Lin S; Lin Y; Liu X; Tan D; Jiang Z
J Nat Med; 2017 Oct; 71(4):685-692. PubMed ID: 28664473
[TBL] [Abstract][Full Text] [Related]
34. Combined treatment for child refractory Mycoplasma pneumoniae pneumonia with ciprofloxacin and glucocorticoid.
Lu A; Wang L; Zhang X; Zhang M
Pediatr Pulmonol; 2011 Nov; 46(11):1093-7. PubMed ID: 21698787
[TBL] [Abstract][Full Text] [Related]
35. Assessment of Genotypic Macrolide Resistance among Mycoplasma pneumoniae Infections in Children in Singapore.
Loo LH; Soong HY; Maiwald M; Tee NW
Ann Acad Med Singap; 2017 Jul; 46(7):290-292. PubMed ID: 28821894
[No Abstract] [Full Text] [Related]
36. Development of macrolide resistance in Mycoplasma pneumoniae-infected Swedish patients treated with macrolides.
Nilsson AC; Jensen JS; Björkman P; Persson K
Scand J Infect Dis; 2014 Apr; 46(4):315-9. PubMed ID: 24447251
[TBL] [Abstract][Full Text] [Related]
37. Occurrence of macrolide-resistant Mycoplasma pneumoniae strains in Germany.
Dumke R; von Baum H; Lück PC; Jacobs E
Clin Microbiol Infect; 2010 Jun; 16(6):613-6. PubMed ID: 19765022
[TBL] [Abstract][Full Text] [Related]
38. Characterization of macrolide resistance of Mycoplasma pneumoniae in children in Shenzhen, China.
Ma Z; Zheng Y; Deng J; Ma X; Liu H
Pediatr Pulmonol; 2014 Jul; 49(7):695-700. PubMed ID: 23861188
[TBL] [Abstract][Full Text] [Related]
39. Low rate of macrolide resistance in Mycoplasma pneumoniae strains in Germany between 2009 and 2012.
Dumke R; Lück C; Jacobs E
Antimicrob Agents Chemother; 2013 Jul; 57(7):3460. PubMed ID: 23650170
[No Abstract] [Full Text] [Related]
40. Macrolide-resistant Mycoplasma pneumoniae in adults with community-acquired pneumonia.
Miyashita N; Oka M; ; Kawai Y; Yamaguchi T; Ouchi K
Int J Antimicrob Agents; 2010 Oct; 36(4):384-5. PubMed ID: 20674283
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
